Parameter | Cutoff | Univariate | Multivariate | ||
---|---|---|---|---|---|
HR (95% CI) | P | HR (95% CI) | P | ||
Age (years) | Continuous | 1.00 (0.98–1.02) per score | 0.98 | ||
Sex | Male | Reference | 0.80 | ||
Female | 0.94 (0.56–1.50) | ||||
ECOG PS | 0 | Reference | 0.043* | Reference | 0.13 |
≥ 1 | 1.57 (1.00–2.39) | 1.41 (0.90–2.19) | |||
eGFR (mL/min/1.73 m2) | < 60 | Reference | 0.15 | ||
≥ 60 | 1.36 (0.89–2.06) | ||||
Primary site | Bladder | Reference | 0.52 | ||
Upper urinary tract | 0.84 (0.54–1.31) | ||||
Both | 1.18 (0.63–2.08) | ||||
Resection of primary site | No | Reference | 0.018* | Reference | 0.047* |
Yes | 0.61 (0.41–0.92) | 0.66 (0.43–0.99) | |||
Prior neoadjuvant/adjuvant chemotherapy | No | Reference | 0.66 | ||
Yes | 1.15 (0.58–2.08) | ||||
Lymph node metastasis | No | Reference | 0.31 | ||
Yes | 1.24 (0.82–1.92) | ||||
Lung metastasis | No | Reference | 0.68 | ||
Yes | 1.09 (0.71–1.64) | ||||
Bone metastasis | No | Reference | 0.48 | ||
Yes | 0.80 (0.41–1.42) | ||||
Liver metastasis | No | Reference | 0.22 | ||
Yes | 1.45 (0.77–2.51) | ||||
First-line regimen | Full-dose GC | Reference | 0.80 | ||
Dose-reduced GC | 0.95 (0.56–1.57) | ||||
GCa | 0.85 (0.53–1.36) |